特利加压素治疗肝硬化肝肾综合征临床观察

Observation of terHpressin＇ s effects on liver cirrhosis with hepatorenal syndrome

目的观察特利加压素对改善肝硬化肝肾综合征（HRS）患者肾功能的作用。方法15例肝硬化HRS患者分两组，在综合治疗的基础上，T组使用特利加压素，D组使用多巴胺。治疗期间观察两组患者尿量、血尿素氮、血肌酐及临床症状、腹水消长情况、副作用和终止治疗事件。结果疗程结束时，T组7例患者尿量由治疗前（480±74）ml／d增加到治疗后（2220±206）ml/d，血尿素氮由治疗前（25．6±2．6）mmol／l降到治疗后（9．0±1．8）mmol／l，血肌酐由治疗前（212．1±21．7）umol／l降至治疗后（121．1±16．7）umol／1，三者与D组比较均有显著差异（P〈0．01）。T组临床症状、腹水消长情况较D组明显改善，而且7例均未出现明显副作用。结论特利加压素能明显改善HRS患者的肾功能，对治疗HRS有确切的疗效。

Objective To observe Terlipressin＇ s effects of renal function in liver cirrhosis patients with bepatorenal syndrome （HRS）. Methods 15 HRS cases were divided into two groups. On top of conventional treatment, one group was given Terlipressin （T-group）, and the other was given Dopamine （D-greup）. The observation was conducted on total urine volume, BUN, and SCr. Results Upon completion of the treatment, T-group was seen an increased urine volume from （480 ± 74） m]/day to （2220 ± 206） ml/day, reflecting a significant increase than that of group-D （P〈0.05）; BUN decreased from （25.6±2.6） mmol/1 to （9.0±1.8） mmol/l; so did SCr, from （212.1 ±21.7） umol/l to （121.1 ± 16.7） umol/1. T-group achieved a better result in all three indicators than D-group （P〈 0.01）. Conclusion Terlipressin is considered being effective in improving renal function in patients with HRS.